ClinicalTrials.gg
CompletedNCT00318955Updated Mar 20, 2017

Post-Marketing Clinical Study to Assess Efficacy and Safety of Dexmedetomidine in Post-Operative Patients

A Phase 4 interventional study of Dexmedetomidine and Propofol in Conscious Sedation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 13 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2017-03-20.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess efficacy and safety of dexmedetomidine at the time of extubation and after extubation, in patients requiring postoperative sedation in the ICU.

Read the detailed description

The study is to conduct as a phase IV post-marketing clinical study in accordance with the approval condition of dexmedetomidine hydrochloride in Japan. The study will compare the use of dexmedetomidine in patient management at the time of extubation with other sedative/ analgesic management, Comparison is made in the use of dexmedetomidine in patient management between a group in which management is performed with dexmedetomidine and a group in which standard management is performed with propofol in patients requiring postoperative sedation in the ICU The usefulness of dexmedetomidine during postextubation period is also evaluated.

02

Conditions studied

  • Conscious Sedation

Keywords

  • Dexmedetomidine, Sedation, Extubation, Phase 4
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient or legally acceptable representative (if acceptable by Institutional Review Board/Ethics Committee) has signed and dated the after the study has been fully explained.
  • Patient is male or female; at least 20 years of age.
  • Patient who is in condition of American Society of Anesthesiology (ASA) I to III Class preoperatively
  • Patient is orally intubated and anticipated to require sedation for mechanical ventilation for a minimum period of 4 hours following open-heart surgery, coronary artery bypass grafting (CABG), or major vascular surgery
  • If patient is female with child bearing potential, she is to be non-pregnant, and not lactating

Exclusion criteria

Exclusion Criteria:

  • Patient with serious disturbance of the central nervous system (disturbance of consciousness).
  • Patient has undergone or requires intracranial surgery during current hospitalization
  • Patient requires muscle relaxant drugs after admission to the ICU (except when an endotracheal tube is reinserted).
  • Patient requires epidural or intrathecal administration of analgesia/anesthesia after surgery and during their ICU stay.
  • Patients for whom propofol or opioids are .
  • Patient has known or suspected allergies to any medication that might be administered during the course of the study.
  • Patient is obese ( >35)
  • Patient was recently hospitalized for drug overdose
  • Patient for whom alpha-2 antagonists or alpha-2 agonists are contraindicated
  • Patient is currently or previously treated, within 30 days before the start of the study, with an alpha-2 antagonist or alpha-2 receptor agonist.
  • Patient has participated in another clinical study within 30 days prior to admission to the ICU and patient is currently participating in another clinical study.
  • Patient was diagnosed with severe symptoms and judged likely to die within 24 hours.
  • Patient is considered unable to undergo all procedures required by the protocol.
  • Patient with excessive bleeding that is likely require reoperation.
  • Patient with an of \< 30%.
  • Patient, in the opinion of the investigator or subinvestigator in the post-marketing clinical study, that has symptoms or factors that may increase his/her risk as a result of the clinical study, or that may not provide sufficient study data.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine group

    Drug: Dexmedetomidine

  • Active comparator
    Propofol group

    Drug: Propofol

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of patients who maintained a Richmond Agitation-Sedation score =0, -1, -2

    Time frame: Continuously from 1 hour before extubation or end of propofol infusion before extubation, whichever is later, to 1 hour after extubation

Secondary outcomes

  1. Variations in vital signs (blood pressure and heart rate) in patients

    Time frame: From 10 minutes before extubation to 10 minutes after extubation

  2. Percentage of patients who required analgesia and received supplemental fentanyl before and after extubation

    Time frame: From 7 days prior to surgery to the start of surgery, and from the end of surgery to 48 hrs after the start of infusion

  3. Percentage of patients with a total score of 3 on the Behavioral Pain Scale just before extubation

    Time frame: 10±2 minutes before extubation, 2±1 minutes after extubation

  4. Percentage of patients who required supplemental sedation after extubation

    Time frame: After extubation to 24 hours after the start of study drug infusion.

  5. Percentage of patients who require post-extubation analgesia and who received supplemental fentanyl after extubation

    Time frame: After extubation to 24 hours after the start of study drug infusion.

  6. Amount of supplemental fentanyl required after extubation

    Time frame: After extubation to 24 hours after the start of study drug infusion.

  7. Ratio of time with a Richmond Agitation-Sedation score ≥+1

    Time frame: From 1 hour before extubation or the end of propofol infusion before extubation, whichever was later, to 1 hour after extubation

  8. Distribution of Richmond Agitation-Sedation score most frequently recorded while intubated

    Time frame: From the start of study drug administration to 1 hour before the expected time of extubation.

  9. Ease of patient management on the basis of a questionnaire to physicians and nurses

    Time frame: Conducted to the greatest possible extent, at ICU discharge or at 36 hours after the start of drug administration, whichever is earlier (in Part II only).

  10. Assessment of interactions between dexmedetomidine and propofol or fentanyl

    Time frame: After propofol or fentanyl administration (Pre-dose and Post dose [5 and 10 minutes])

  11. Patient self-evaluation of experiences during their stay in the ICU

    Time frame: Conducted to the greatest possible extent, at ICU discharge or at 36 hours after the start of drug administration, whichever is earlier (in Part II only).

07

Study locations

13 sites
  • Hirosaki University Hospital
    Hirosaki-shi, Aomori, Japan
  • Kyushu University Hospital
    Higashi-ku, Fukuoka, Japan
  • Kyoto University Hospital
    Sakyoku, Kyoto, Japan
  • Osaka City General Hospital
    Miyakojima-ku, Osaka, Japan
  • Kinki University Hospital
    Osaka-Sayama-Shi, Osaka, Japan
  • Osaka University Hospital
    Suita, Osaka, Japan
  • Hamamatsu University Hospital
    Hamamatsu-City, Shizuoka, Japan
  • Nippon Medical School Hospital
    Bunkyo-ku, Tokyo, Japan
  • Showa University Hospital
    Shinagawa-ku, Tokyo, Japan
  • Tokyo Women's Medical University Hospital
    Shinjuku-ku, Tokyo, Japan
  • Kagoshima University Medical and Dental Hospital
    Kagoshima, Japan
  • Nagasaki University Hospital of Medicine and Dentistry
    Nagasaki, Japan
  • Okayama University Hospital of Medicine and Dentistry
    Okayama, Japan
08

References and documents

Publications

  • Aitkenhead AR. Analgesia and sedation in intensive care. Br J Anaesth. 1989 Aug;63(2):196-206. doi: 10.1093/bja/63.2.196. No abstract available. PubMed 2669909 ↗
  • Minoru Kaneshiro. Analgesic and Sedatin during mechanical ventilation, ICU and CCU 14:14643-648,1990
  • Syu Matsukawa, et.al.Sedation during ventilation control, ICU and CCU 14:603-608,1990
  • Megumu Tagami et.al. Post-operative analgesic and sedation control,
  • Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet. 1983 May-Jun;8(3):233-52. doi: 10.2165/00003088-198308030-00003. PubMed 6133664 ↗
  • Hidekazu Yukioka, et.al. Current status of analgesic and sedation control in ICU. Japan ICU Treatment Association's Magazine 1:13-19, 1994
  • Masayoshi Hyodo et.al. Anesthetic Science, 10th edition, Kinpodo, ppl 213-219
  • Ikuto Yoshiya. Section 4; Pharmacology for Anesthesia, Introduction to Anesthesiology, 7th edition, Nagai Shoten,pp439-447, 1993
  • Ikuto Yoshiya: Sedation and Analgesia for Intensive Care Patients. Anesthesia 21(2):2-6, 333-337, 2000
  • Costas Katsanoulas. Concluding Remarks: Redefining Intensive Care Unit Sedation, International Congress and Symposium Series 221, 83-88
  • Mantz,J., Singer,M. Importance of Patient Orientation and Rousability as Components of Intensive Care Unit Sedation, International Congress and Symposium Series 221, 23-29
  • Hewitt PB. Subjective follow-up of patients from a surgical intensive therapy ward. Br Med J. 1970 Dec 12;4(5736):669-73. doi: 10.1136/bmj.4.5736.669. PubMed 4098972 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2006
First posted
Apr 27, 2006
Start
Nov 2005
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Mar 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00318955
Collaborators
Maruishi Pharmaceutical
Responsible party
Sponsor
First posted
Apr 27, 2006
Start date
Nov 2005
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Mar 20, 2017

Study contacts

Misa Kawai
study director · Hospira, now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion